Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma
Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades, but direct evidence for the role of cytotoxic lymphocytes in protecting against spontaneous malignancy has been lacking. As the rejection of many experimental cancers by cytotoxic T lymphocytes and natural k...
Saved in:
| Published in | The Journal of experimental medicine Vol. 192; no. 5; pp. 755 - 760 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
The Rockefeller University Press
05.09.2000
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades, but direct evidence for the role of cytotoxic lymphocytes in protecting against spontaneous malignancy has been lacking. As the rejection of many experimental cancers by cytotoxic T lymphocytes and natural killer cells is dependent on the pore-forming protein perforin (pfp), we examined pfp-deficient mice for increased cancer susceptibility. Here we show that pfp-deficient mice have a high incidence of malignancy in distinct lymphoid cell lineages (T, B, NKT), indicating a specific requirement for pfp in protection against lymphomagenesis. The susceptibility to lymphoma was accentuated by simultaneous lack of expression of the p53 gene, mutations in which also commonly predispose to human malignancies, including lymphoma. In contrast, the incidence and age of onset of sarcoma was unaffected in p53-deficient mice. Pfp-deficient mice were at least 1,000-fold more susceptible to these lymphomas when transplanted, compared with immunocompetent mice in which tumor rejection was controlled by CD8(+) T lymphocytes. This study is the first that implicates direct cytotoxicity by lymphocytes in regulating lymphomagenesis. |
|---|---|
| AbstractList | Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades, but direct evidence for the role of cytotoxic lymphocytes in protecting against spontaneous malignancy has been lacking. As the rejection of many experimental cancers by cytotoxic T lymphocytes and natural killer cells is dependent on the pore-forming protein perform (pfp), we examined pfp-deficient mice for increased cancer susceptibility. Here we show that pfp-deficient mice have a high incidence of malignancy in distinct lymphoid cell lineages (T, B, NKT), indicating a specific requirement for pfp in protection against lymphomagenesis. The susceptibility to lymphoma was accentuated by simultaneous lack of expression of the p53 gene, mutations in which also commonly predispose to human malignancies, including lymphoma. In contrast, the incidence and age of onset of sarcoma was unaffected in p53-deficient mice. Pfp-deficient mice were at least 1,000-fold more susceptible to these lymphomas when transplanted, compared with immunocompetent mice in which tumor rejection was controlled by CD8 super(+) T lymphocytes. This study is the first that implicates direct cytotoxicity by lymphocytes in regulating lymphomagenesis. Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades, but direct evidence for the role of cytotoxic lymphocytes in protecting against spontaneous malignancy has been lacking. As the rejection of many experimental cancers by cytotoxic T lymphocytes and natural killer cells is dependent on the pore-forming protein perforin (pfp), we examined pfp-deficient mice for increased cancer susceptibility. Here we show that pfp-deficient mice have a high incidence of malignancy in distinct lymphoid cell lineages (T, B, NKT), indicating a specific requirement for pfp in protection against lymphomagenesis. The susceptibility to lymphoma was accentuated by simultaneous lack of expression of the p53 gene, mutations in which also commonly predispose to human malignancies, including lymphoma. In contrast, the incidence and age of onset of sarcoma was unaffected in p53-deficient mice. Pfp-deficient mice were at least 1,000-fold more susceptible to these lymphomas when transplanted, compared with immunocompetent mice in which tumor rejection was controlled by CD8 + T lymphocytes. This study is the first that implicates direct cytotoxicity by lymphocytes in regulating lymphomagenesis. Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades, but direct evidence for the role of cytotoxic lymphocytes in protecting against spontaneous malignancy has been lacking. As the rejection of many experimental cancers by cytotoxic T lymphocytes and natural killer cells is dependent on the pore-forming protein perforin (pfp), we examined pfp-deficient mice for increased cancer susceptibility. Here we show that pfp-deficient mice have a high incidence of malignancy in distinct lymphoid cell lineages (T, B, NKT), indicating a specific requirement for pfp in protection against lymphomagenesis. The susceptibility to lymphoma was accentuated by simultaneous lack of expression of the p53 gene, mutations in which also commonly predispose to human malignancies, including lymphoma. In contrast, the incidence and age of onset of sarcoma was unaffected in p53-deficient mice. Pfp-deficient mice were at least 1,000-fold more susceptible to these lymphomas when transplanted, compared with immunocompetent mice in which tumor rejection was controlled by CD8(+) T lymphocytes. This study is the first that implicates direct cytotoxicity by lymphocytes in regulating lymphomagenesis. |
| Author | Street, S E Godfrey, D I Thia, K Y MacGregor, D Trapani, J A Smyth, M J |
| Author_xml | – sequence: 1 givenname: M J surname: Smyth fullname: Smyth, M J organization: Austin Research Institute, Heidelberg, 3084, Victoria, Australia – sequence: 2 givenname: K Y surname: Thia fullname: Thia, K Y – sequence: 3 givenname: S E surname: Street fullname: Street, S E – sequence: 4 givenname: D surname: MacGregor fullname: MacGregor, D – sequence: 5 givenname: D I surname: Godfrey fullname: Godfrey, D I – sequence: 6 givenname: J A surname: Trapani fullname: Trapani, J A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10974040$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtLAzEUhYNU7EOXbmVW7qbmnclGkOILCgrqOmQyGZsyM6lJWuy_d0qL1JWru7gfh3P4xmDQ-c4CcIngFMGC3ixtO0UST9lUMHYCRohRmEtGigEYQYhxjiAUQzCOcQkhopTxMzBEUAoKKRyBt1cbah9cl7e2cjrZKjPb5JP_dsalbeZiZoJLzugm67ksrsPGuqbRnbGZr7O48l3SnfXrmDXbdrXwrT4Hp7Vuor043An4eLh_nz3l85fH59ndPDcM05RXlONSMyRgWYoCFwUvai5LbEhJCytrwzXGshAYCobKskYVkzU3tCKIayowmYDbfe5qXfbtje1S0I1aBdfqsFVeO_X307mF-vQbhZEkmMs-4PoQEPzX2sakWheN3a3bDVICY0qgRP-CSHBChBA9mO9BE3yMwda_bRBUO1-q96V6X4qp3lfPXx1POKL3gsgPdj-VNQ |
| CitedBy_id | crossref_primary_10_1002_pbc_25646 crossref_primary_10_1158_0008_5472_CAN_08_2654 crossref_primary_10_1371_journal_pone_0186997 crossref_primary_10_1016_j_immuni_2006_09_010 crossref_primary_10_1002_pbc_30677 crossref_primary_10_1038_86297 crossref_primary_10_1038_nri1961 crossref_primary_10_4161_onci_24185 crossref_primary_10_1073_pnas_0809008106 crossref_primary_10_1667_RADE_20_00221_1 crossref_primary_10_3390_cancers10030085 crossref_primary_10_1038_s41423_019_0224_2 crossref_primary_10_4049_jimmunol_171_2_608 crossref_primary_10_1189_jlb_1107774 crossref_primary_10_1053_j_gastro_2007_11_061 crossref_primary_10_4049_jimmunol_180_12_8004 crossref_primary_10_1083_jcb_200510072 crossref_primary_10_3389_fimmu_2021_768989 crossref_primary_10_1038_cdd_2013_59 crossref_primary_10_1007_s00281_004_0197_8 crossref_primary_10_15741_revbio_11_e1614 crossref_primary_10_1016_j_ccr_2006_05_025 crossref_primary_10_1080_02656730210146926 crossref_primary_10_1073_pnas_0503852102 crossref_primary_10_1146_annurev_immunol_031210_101324 crossref_primary_10_1002_cncr_32011 crossref_primary_10_1007_s00005_010_0102_1 crossref_primary_10_1038_ni_1655 crossref_primary_10_4161_onci_22337 crossref_primary_10_1097_MPH_0000000000001450 crossref_primary_10_1002_ijc_23090 crossref_primary_10_1634_theoncologist_2015_0282 crossref_primary_10_1007_s10875_006_9040_4 crossref_primary_10_1084_jem_20040776 crossref_primary_10_3390_cancers14071681 crossref_primary_10_1038_cdd_2013_189 crossref_primary_10_1016_j_bcp_2004_05_043 crossref_primary_10_1007_BF02983991 crossref_primary_10_1189_jlb_71_6_907 crossref_primary_10_1016_j_smim_2006_03_005 crossref_primary_10_1016_S0213_9251_02_72582_3 crossref_primary_10_1016_S1535_6108_02_00130_7 crossref_primary_10_1182_blood_2005_06_2234 crossref_primary_10_1111_j_1349_7006_2004_tb03248_x crossref_primary_10_3389_fimmu_2014_00197 crossref_primary_10_1146_annurev_immunol_032414_112049 crossref_primary_10_1002_pbc_27929 crossref_primary_10_1038_nri1983 crossref_primary_10_1002_eji_201847771 crossref_primary_10_1158_0008_5472_CAN_14_1848 crossref_primary_10_1016_j_vascn_2010_12_001 crossref_primary_10_1034_j_1600_065X_2002_18802_x crossref_primary_10_1177_1933719115602762 crossref_primary_10_1016_j_cytogfr_2021_10_005 crossref_primary_10_1016_j_ijbiomac_2021_08_225 crossref_primary_10_1128_JVI_02528_08 crossref_primary_10_1186_1471_2407_10_121 crossref_primary_10_1016_j_semcancer_2018_04_006 crossref_primary_10_1016_j_trim_2020_101295 crossref_primary_10_1073_pnas_0903815106 crossref_primary_10_1080_17513758_2014_913718 crossref_primary_10_23736_S0026_4806_20_06607_0 crossref_primary_10_1038_srep07824 crossref_primary_10_3390_ijms151120209 crossref_primary_10_1016_j_immuni_2008_02_016 crossref_primary_10_1007_s12026_011_8242_x crossref_primary_10_1016_j_xinn_2023_100452 crossref_primary_10_3389_fimmu_2014_00185 crossref_primary_10_5847_wjem_j_issn_1920_8642_2013_02_008 crossref_primary_10_1038_nm1101_1178 crossref_primary_10_1038_nri2604 crossref_primary_10_1038_ni1102_991 crossref_primary_10_1371_journal_pone_0007512 crossref_primary_10_1172_JCI31405 crossref_primary_10_1002_hep_20204 crossref_primary_10_1080_10428194_2017_1341978 crossref_primary_10_1016_j_virol_2006_08_044 crossref_primary_10_1056_NEJMoa041432 crossref_primary_10_1038_ni1102_999 crossref_primary_10_3390_jcm5090076 crossref_primary_10_2217_fon_10_159 crossref_primary_10_1111_j_1365_2567_2007_02587_x crossref_primary_10_1111_j_0105_2896_2004_00199_x crossref_primary_10_3389_fonc_2021_626818 crossref_primary_10_1016_j_immuni_2011_04_007 crossref_primary_10_1155_2010_104918 crossref_primary_10_1016_j_preteyeres_2009_06_002 crossref_primary_10_1016_j_yexmp_2009_01_010 crossref_primary_10_1038_ni880 crossref_primary_10_1038_s41573_019_0052_1 crossref_primary_10_1089_gtmb_2009_0045 crossref_primary_10_1097_00062752_200201000_00008 crossref_primary_10_1371_journal_pone_0002150 crossref_primary_10_4049_jimmunol_1701302 crossref_primary_10_1016_j_ccr_2005_10_018 crossref_primary_10_1007_s13277_015_3285_6 crossref_primary_10_1371_journal_pone_0040146 crossref_primary_10_1038_nri819 crossref_primary_10_1038_mi_2015_125 crossref_primary_10_1182_blood_2007_02_072850 crossref_primary_10_1007_s00281_011_0270_z crossref_primary_10_1016_j_immuni_2011_04_019 crossref_primary_10_1016_j_cytogfr_2020_06_005 crossref_primary_10_1016_S1074_7613_03_00050_5 crossref_primary_10_1038_sj_leu_2403414 crossref_primary_10_1158_0008_5472_CAN_09_0685 crossref_primary_10_1073_pnas_1630663100 crossref_primary_10_3390_jpm14040431 crossref_primary_10_4049_jimmunol_1101988 crossref_primary_10_3390_cancers7020736 crossref_primary_10_1016_S1074_7613_02_00502_2 crossref_primary_10_1038_s41577_018_0009_3 crossref_primary_10_1038_sj_emboj_7601650 crossref_primary_10_4049_jimmunol_1301248 crossref_primary_10_1038_sj_onc_1210491 crossref_primary_10_1089_vim_2008_0036 crossref_primary_10_1111_j_1600_065X_2007_00575_x crossref_primary_10_1080_10428190500051893 crossref_primary_10_1093_immadv_ltaa001 crossref_primary_10_1038_sj_leu_2404299 crossref_primary_10_1002_eji_200636726 crossref_primary_10_1007_s12026_009_8124_7 crossref_primary_10_1038_nri3839 crossref_primary_10_1016_j_canlet_2008_09_037 crossref_primary_10_4049_jimmunol_171_2_515 crossref_primary_10_1016_j_smim_2019_03_001 crossref_primary_10_1016_j_beha_2006_06_002 crossref_primary_10_1080_2162402X_2016_1268310 crossref_primary_10_3389_fimmu_2023_1151166 crossref_primary_10_1074_jbc_M413303200 crossref_primary_10_1111_j_1749_6632_2011_06307_x crossref_primary_10_3390_cancers13164129 crossref_primary_10_1038_35074122 crossref_primary_10_1016_j_pep_2013_11_009 crossref_primary_10_3390_cells7020012 crossref_primary_10_3390_ijms24010147 crossref_primary_10_1084_jem_20011171 crossref_primary_10_1155_2015_495430 crossref_primary_10_1371_journal_pone_0018164 crossref_primary_10_4049_jimmunol_0801878 crossref_primary_10_1016_S0952_7915_03_00114_6 crossref_primary_10_4161_onci_1_2_18481 crossref_primary_10_4049_jimmunol_1103822 crossref_primary_10_1182_blood_2016_12_756585 crossref_primary_10_1158_1078_0432_CCR_07_1161 crossref_primary_10_1038_cdd_2009_212 crossref_primary_10_1016_j_immuni_2005_02_003 crossref_primary_10_1159_000512326 crossref_primary_10_1080_2162402X_2014_998538 crossref_primary_10_3390_vetsci10050336 crossref_primary_10_1016_j_exphem_2007_12_006 crossref_primary_10_1038_icb_2012_30 crossref_primary_10_1080_14712598_2022_2154601 crossref_primary_10_1016_j_critrevonc_2004_12_009 crossref_primary_10_1038_ni1205_1207 crossref_primary_10_2217_imt_09_50 crossref_primary_10_1146_annurev_immunol_22_012703_104803 crossref_primary_10_1007_s10555_017_9694_9 crossref_primary_10_1038_s41568_020_0263_0 crossref_primary_10_1074_jbc_M602007200 crossref_primary_10_1097_01_aids_0000433236_55937_cb crossref_primary_10_1016_j_omto_2023_01_006 crossref_primary_10_1016_j_semcancer_2022_02_003 crossref_primary_10_1038_sj_cgt_7700678 crossref_primary_10_1080_2162402X_2017_1365997 crossref_primary_10_1007_s00405_018_4956_x crossref_primary_10_1016_j_ctarc_2017_05_002 crossref_primary_10_1016_j_intimp_2022_109569 crossref_primary_10_1158_1078_0432_CCR_15_0685 crossref_primary_10_1007_s10875_013_9907_0 crossref_primary_10_3389_fonc_2018_00219 crossref_primary_10_1111_j_1365_2249_2010_04302_x crossref_primary_10_1158_0008_5472_CAN_12_1337 crossref_primary_10_4049_jimmunol_168_7_3484 crossref_primary_10_1038_s41467_024_45750_w crossref_primary_10_3389_fcell_2022_933113 crossref_primary_10_1016_j_iac_2008_01_010 crossref_primary_10_3390_cancers16020312 crossref_primary_10_1371_journal_pone_0015549 crossref_primary_10_1021_jm401604x crossref_primary_10_4049_jimmunol_173_3_1738 crossref_primary_10_1146_annurev_immunol_20_100201_131730 crossref_primary_10_1016_j_coi_2004_01_003 crossref_primary_10_3390_cells9040855 crossref_primary_10_4049_jimmunol_168_9_4472 crossref_primary_10_1016_S1472_6483_10_60574_3 crossref_primary_10_4049_jimmunol_175_9_5586 crossref_primary_10_3389_fimmu_2020_00490 crossref_primary_10_1038_35093109 crossref_primary_10_1016_j_coi_2004_01_009 crossref_primary_10_1016_j_cell_2016_01_002 crossref_primary_10_3389_fimmu_2020_601405 crossref_primary_10_3390_ijms21103726 crossref_primary_10_1007_s11095_018_2365_x crossref_primary_10_1016_j_semcancer_2011_12_004 crossref_primary_10_1038_nrc1252 crossref_primary_10_1111_iji_12103 crossref_primary_10_1002_path_2865 crossref_primary_10_1084_jem_20011836 crossref_primary_10_1038_s41577_018_0061_z crossref_primary_10_1097_MPH_0000000000002141 crossref_primary_10_1200_JCO_2010_33_4623 crossref_primary_10_1038_sj_cgt_7700540 crossref_primary_10_1016_j_immuni_2004_07_017 crossref_primary_10_1016_j_semcancer_2015_07_004 crossref_primary_10_1038_nri2671 crossref_primary_10_1111_j_1365_2141_2004_05305_x crossref_primary_10_1038_s41598_021_03324_6 crossref_primary_10_1182_blood_2006_04_014480 crossref_primary_10_1182_blood_2009_01_198564 crossref_primary_10_1016_j_copbio_2017_03_024 crossref_primary_10_1016_S2352_3026_15_00223_9 crossref_primary_10_1093_cei_uxac006 crossref_primary_10_1038_gt_2008_47 crossref_primary_10_1038_nrc_2016_91 crossref_primary_10_1111_j_1440_1711_2005_01409_x crossref_primary_10_1016_j_clnesp_2022_11_001 crossref_primary_10_1016_j_cell_2019_04_041 crossref_primary_10_1016_j_mam_2022_101152 crossref_primary_10_1016_S0952_7915_02_00315_1 crossref_primary_10_1016_j_bbrc_2014_12_027 crossref_primary_10_1073_pnas_201398198 crossref_primary_10_3109_10428194_2011_625099 crossref_primary_10_1097_PPO_0000000000000005 crossref_primary_10_1038_nrc928 crossref_primary_10_1111_his_12706 crossref_primary_10_4049_jimmunol_175_5_3235 crossref_primary_10_1016_S0952_7915_00_00257_0 crossref_primary_10_1586_14760584_1_3_303 crossref_primary_10_1038_nri911 crossref_primary_10_4049_jimmunol_176_10_6347 crossref_primary_10_1016_j_critrevonc_2009_06_002 crossref_primary_10_1016_j_it_2007_04_003 crossref_primary_10_1016_S0306_9877_02_00359_6 crossref_primary_10_1007_s00281_004_0195_x crossref_primary_10_1016_S2352_3026_15_00250_1 crossref_primary_10_1186_s13008_015_0012_z crossref_primary_10_1016_j_jri_2022_103676 crossref_primary_10_1084_jem_193_6_661 crossref_primary_10_1158_0008_5472_CAN_06_4084 crossref_primary_10_1111_j_1462_5822_2008_01191_x crossref_primary_10_1038_nm_3442 crossref_primary_10_1002_ijc_27755 crossref_primary_10_3389_fimmu_2024_1388176 crossref_primary_10_1016_S1359_6101_01_00038_7 crossref_primary_10_1006_viro_2002_1754 crossref_primary_10_1006_cimm_2001_1896 crossref_primary_10_1016_j_clon_2007_10_011 crossref_primary_10_1016_j_imlet_2003_08_005 crossref_primary_10_1084_jem_20050953 crossref_primary_10_1016_j_semcancer_2007_06_009 crossref_primary_10_1111_j_0105_2896_2010_00896_x crossref_primary_10_18632_oncotarget_403 crossref_primary_10_3389_fimmu_2017_01124 crossref_primary_10_4049_jimmunol_0903767 crossref_primary_10_1046_j_0818_9641_2003_01151_x crossref_primary_10_1084_jem_20020063 crossref_primary_10_1007_s12026_014_8507_2 crossref_primary_10_1111_j_0105_2896_2010_00909_x crossref_primary_10_1038_ni0705_646 crossref_primary_10_1111_imr_12938 crossref_primary_10_3390_cancers15072024 crossref_primary_10_1042_CBI20090206 crossref_primary_10_1189_jlb_0208107 crossref_primary_10_1038_sj_cdd_4402235 crossref_primary_10_1084_jem_20190457 crossref_primary_10_1189_jlb_70_1_18 crossref_primary_10_4049_jimmunol_2000734 crossref_primary_10_1182_blood_2003_06_2171 crossref_primary_10_4993_acrt_12_9 crossref_primary_10_1002_ctm2_37 crossref_primary_10_1186_1897_4287_9_9 crossref_primary_10_1034_j_1600_065X_2002_18801_x crossref_primary_10_1016_j_immuni_2007_08_014 crossref_primary_10_1111_j_0906_6705_2003_00094_x crossref_primary_10_1111_j_1365_2567_2010_03299_x crossref_primary_10_1517_14728222_9_5_1031 crossref_primary_10_5581_1516_8484_20110076 crossref_primary_10_1016_S0211_3449_05_73618_3 crossref_primary_10_1016_j_leukres_2017_12_011 crossref_primary_10_1016_j_immuni_2019_12_018 crossref_primary_10_12659_MSMBR_895563 crossref_primary_10_1016_j_yexcr_2014_03_014 crossref_primary_10_3389_fimmu_2014_00360 crossref_primary_10_1097_01_cji_0000203079_35612_c8 crossref_primary_10_3390_cancers12020316 crossref_primary_10_1182_blood_2005_03_1019 crossref_primary_10_1039_D1SC06366A crossref_primary_10_1111_j_1365_3083_2012_02736_x crossref_primary_10_1016_j_dnarep_2005_08_004 crossref_primary_10_1172_JCI77181 crossref_primary_10_1002_cyto_a_20023 crossref_primary_10_1016_j_leukres_2010_06_016 crossref_primary_10_1038_sj_cdd_4402244 crossref_primary_10_3389_fmmed_2023_1140977 crossref_primary_10_1155_2012_192719 crossref_primary_10_1038_nrc_2016_2 crossref_primary_10_3389_fimmu_2021_633205 crossref_primary_10_3389_fimmu_2023_1164284 crossref_primary_10_1158_1541_7786_MCR_12_0115 crossref_primary_10_1111_j_1399_0039_2008_01088_x crossref_primary_10_1158_1541_7786_MCR_11_0185 crossref_primary_10_1016_j_cll_2017_06_001 crossref_primary_10_1515_bc_2010_088 crossref_primary_10_1097_00002281_200307000_00011 crossref_primary_10_1177_2324709616684514 crossref_primary_10_1016_j_trecan_2017_04_001 crossref_primary_10_1016_S0952_7915_03_00107_9 crossref_primary_10_1038_leu_2008_193 crossref_primary_10_3389_fimmu_2019_02073 crossref_primary_10_1007_s00262_006_0183_1 crossref_primary_10_3390_ijms22031255 crossref_primary_10_3390_biomedicines9101383 crossref_primary_10_3389_fphar_2022_980742 crossref_primary_10_4049_jimmunol_1701124 crossref_primary_10_1002_1521_4141_200101_31_1_39__AID_IMMU39_3_0_CO_2_1 crossref_primary_10_1038_labinvest_2009_91 crossref_primary_10_1080_2162402X_2015_1137418 crossref_primary_10_1007_s11481_016_9670_0 crossref_primary_10_1517_14728222_2012_681378 crossref_primary_10_4049_jimmunol_174_4_2124 crossref_primary_10_3390_antib1020172 crossref_primary_10_1126_science_1203486 crossref_primary_10_1016_j_healun_2014_09_038 crossref_primary_10_1189_jlb_1105656 crossref_primary_10_3389_fcell_2019_00052 crossref_primary_10_1084_jem_20031981 crossref_primary_10_1097_01_tp_0000250935_41034_2d crossref_primary_10_1016_j_ajpath_2023_10_008 crossref_primary_10_2174_1574892816666210201114712 crossref_primary_10_1159_000342166 crossref_primary_10_1097_00005344_200108000_00016 crossref_primary_10_3389_fimmu_2016_00365 crossref_primary_10_1007_s00281_004_0192_0 crossref_primary_10_1038_onc_2008_268 crossref_primary_10_1016_j_intimp_2018_06_001 crossref_primary_10_4049_jimmunol_169_10_5377 crossref_primary_10_1016_j_oraloncology_2016_09_010 crossref_primary_10_1111_j_0105_2896_2010_00890_x crossref_primary_10_1074_jbc_M604544200 crossref_primary_10_3390_jcm2030136 crossref_primary_10_1158_0008_5472_CAN_04_4269 crossref_primary_10_1016_S1471_4906_01_01977_9 crossref_primary_10_1046_j_1440_1711_2002_01108_x crossref_primary_10_1111_bjh_12728 |
| Cites_doi | 10.1038/356215a0 10.1038/ng0894-480 10.1002/eji.1830220516 10.1016/S0167-5699(99)01488-7 10.1038/284622a0 10.1002/ijc.2910350414 10.4049/jimmunol.154.1.180 10.1159/000386035 10.1101/gad.10.16.2055 10.4049/jimmunol.162.11.6658 10.1016/S0092-8674(00)81871-1 10.1016/S0960-9822(00)00002-6 10.1084/jem.191.4.661 10.1038/ng0994-66 10.1084/jem.171.4.1269 10.1073/pnas.95.13.7556 10.1038/369031a0 10.1146/annurev.immunol.15.1.749 10.1126/science.286.5446.1957 10.1126/science.1978757 10.1128/JVI.73.3.2527-2536.1999 10.1084/jem.184.5.1781 10.4049/jimmunol.131.4.2069 10.1084/jem.187.11.1903 10.1056/NEJM199310283291807 10.1073/pnas.91.23.10854 10.1016/0167-5699(95)80121-9 |
| ContentType | Journal Article |
| Copyright | 2000 The Rockefeller University Press 2000 The Rockefeller University Press |
| Copyright_xml | – notice: 2000 The Rockefeller University Press 2000 The Rockefeller University Press |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 7X8 5PM |
| DOI | 10.1084/jem.192.5.755 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1540-9538 1892-1007 |
| EndPage | 760 |
| ExternalDocumentID | 10_1084_jem_192_5_755 10974040 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X .55 .GJ 0VX 18M 29K 2WC 36B 3O- 4.4 53G 5GY 5RE 5VS 9M8 ABOCM ABZEH ACGFO ACNCT ACPRK ADBBV AENEX AFFNX AFNDN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C45 CGR CS3 CUY CVF D-I DIK DU5 E3Z EBS ECM EIF EJD F5P F9R FRP GX1 HYE H~9 IH2 K-O KQ8 L7B MVM N4W N9A NPM O5R O5S OK1 OVD P2P P6G R.V RHF RHI RPM SJN TR2 TRP UHB VH1 W8F WOQ X7M ZA5 ZGI AAYXX CITATION H13 7T5 H94 7X8 5PM |
| ID | FETCH-LOGICAL-c524t-d462ba5170bb7828868f69b2c3b48e9fc6a2298720751bbf1d59f6c4d316a4723 |
| IEDL.DBID | RPM |
| ISSN | 0022-1007 |
| IngestDate | Tue Sep 17 21:20:37 EDT 2024 Fri Aug 16 12:25:29 EDT 2024 Fri Aug 16 05:44:27 EDT 2024 Fri Aug 23 00:16:31 EDT 2024 Thu May 23 23:48:13 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c524t-d462ba5170bb7828868f69b2c3b48e9fc6a2298720751bbf1d59f6c4d316a4723 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193269/ |
| PMID | 10974040 |
| PQID | 17633777 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2193269 proquest_miscellaneous_72243091 proquest_miscellaneous_17633777 crossref_primary_10_1084_jem_192_5_755 pubmed_primary_10974040 |
| PublicationCentury | 2000 |
| PublicationDate | 20000905 |
| PublicationDateYYYYMMDD | 2000-09-05 |
| PublicationDate_xml | – month: 9 year: 2000 text: 20000905 day: 5 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of experimental medicine |
| PublicationTitleAlternate | J Exp Med |
| PublicationYear | 2000 |
| Publisher | The Rockefeller University Press |
| Publisher_xml | – name: The Rockefeller University Press |
| References | Smyth (2023072509252636000_R11) 1999; 162 Stutman (2023072509252636000_R25) 1979; 47 Kaplan (2023072509252636000_R22) 1998; 95 Shultz (2023072509252636000_R27) 1995; 154 Melief (2023072509252636000_R3) 1991; 2 Smyth (2023072509252636000_R5) 1990; 171 Kagi (2023072509252636000_R10) 1994; 369 Trapani (2023072509252636000_R8) 1999; 20 Burnet (2023072509252636000_R1) 1970; 13 Liu (2023072509252636000_R7) 1995; 16 Boehm (2023072509252636000_R23) 1997; 15 Talmadge (2023072509252636000_R28) 1980; 284 Stepp (2023072509252636000_R32) 1999; 286 Williams (2023072509252636000_R20) 1994; 7 Gershwin (2023072509252636000_R26) 1983; 131 Kemp (2023072509252636000_R19) 1994; 8 Whiteside (2023072509252636000_R4) 1998; 230 Matloubian (2023072509252636000_R31) 1999; 73 Binder (2023072509252636000_R30) 1998; 187 Thomas (2023072509252636000_R2) 1982; 55 Haliotis (2023072509252636000_R29) 1985; 35 Donehower (2023072509252636000_R17) 1992; 356 Kawasaki (2023072509252636000_R6) 1992; 22 van den Broek (2023072509252636000_R9) 1996; 184 Levine (2023072509252636000_R12) 1997; 88 Jacks (2023072509252636000_R16) 1994; 1 Nacht (2023072509252636000_R21) 1996; 10 Malkin (2023072509252636000_R15) 1990; 250 Hollstein (2023072509252636000_R13) 1994; 22 Smyth (2023072509252636000_R24) 2000; 191 Harris (2023072509252636000_R14) 1993; 329 Walsh (2023072509252636000_R18) 1994; 91 |
| References_xml | – volume: 356 start-page: 215 year: 1992 ident: 2023072509252636000_R17 article-title: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours publication-title: Nature. doi: 10.1038/356215a0 contributor: fullname: Donehower – volume: 7 start-page: 480 year: 1994 ident: 2023072509252636000_R20 article-title: Cooperative tumorigenic effects of germline mutations in Rb and p53 publication-title: Nat. Genet. doi: 10.1038/ng0894-480 contributor: fullname: Williams – volume: 22 start-page: 1215 year: 1992 ident: 2023072509252636000_R6 article-title: Expression of perforin in murine natural killer cells and cytotoxic T lymphocytes in vivo publication-title: Eur. J. Immunol. doi: 10.1002/eji.1830220516 contributor: fullname: Kawasaki – volume: 20 start-page: 351 year: 1999 ident: 2023072509252636000_R8 article-title: CTL granulesevolution of vesicles essential for combating virus infections publication-title: Immunol. Today. doi: 10.1016/S0167-5699(99)01488-7 contributor: fullname: Trapani – volume: 284 start-page: 622 year: 1980 ident: 2023072509252636000_R28 article-title: Role of NK cells in tumour growth and metastasis in beige mice publication-title: Nature. doi: 10.1038/284622a0 contributor: fullname: Talmadge – volume: 35 start-page: 505 year: 1985 ident: 2023072509252636000_R29 article-title: Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice publication-title: Int. J. Cancer. doi: 10.1002/ijc.2910350414 contributor: fullname: Haliotis – volume: 55 start-page: 329 year: 1982 ident: 2023072509252636000_R2 article-title: On immunosurveillance in human cancer publication-title: Yale J. Biol. Med. contributor: fullname: Thomas – volume: 154 start-page: 180 year: 1995 ident: 2023072509252636000_R27 article-title: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice publication-title: J. Immunol. doi: 10.4049/jimmunol.154.1.180 contributor: fullname: Shultz – volume: 2 start-page: 347 year: 1991 ident: 2023072509252636000_R3 article-title: Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms publication-title: Semin. Cancer Biol. contributor: fullname: Melief – volume: 13 start-page: 1 year: 1970 ident: 2023072509252636000_R1 article-title: The concept of immunological surveillance publication-title: Prog. Exp. Tumor Res. doi: 10.1159/000386035 contributor: fullname: Burnet – volume: 10 start-page: 2055 year: 1996 ident: 2023072509252636000_R21 article-title: Mutations in the p53 and SCID genes cooperate in tumorigenesis publication-title: Genes Dev. doi: 10.1101/gad.10.16.2055 contributor: fullname: Nacht – volume: 162 start-page: 6658 year: 1999 ident: 2023072509252636000_R11 article-title: Perforin is a major contributor to NK cell control of tumor metastasis publication-title: J. Immunol. doi: 10.4049/jimmunol.162.11.6658 contributor: fullname: Smyth – volume: 88 start-page: 323 year: 1997 ident: 2023072509252636000_R12 article-title: p53, the cellular gatekeeper for growth and division publication-title: Cell. doi: 10.1016/S0092-8674(00)81871-1 contributor: fullname: Levine – volume: 1 start-page: 1 year: 1994 ident: 2023072509252636000_R16 article-title: Tumor spectrum analysis in p53-mutant mice publication-title: Curr. Biol. doi: 10.1016/S0960-9822(00)00002-6 contributor: fullname: Jacks – volume: 191 start-page: 661 year: 2000 ident: 2023072509252636000_R24 article-title: Differential tumor surveillance by natural killer (NK) and NKT cells publication-title: J. Exp. Med. doi: 10.1084/jem.191.4.661 contributor: fullname: Smyth – volume: 8 start-page: 66 year: 1994 ident: 2023072509252636000_R19 article-title: p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis publication-title: Nat. Genet. doi: 10.1038/ng0994-66 contributor: fullname: Kemp – volume: 171 start-page: 1269 year: 1990 ident: 2023072509252636000_R5 article-title: Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells publication-title: J. Exp. Med. doi: 10.1084/jem.171.4.1269 contributor: fullname: Smyth – volume: 95 start-page: 7556 year: 1998 ident: 2023072509252636000_R22 article-title: Demonstration of an interferon γ–dependent tumor surveillance system in immunocompetent mice publication-title: Proc. Natl. Acad. Sci. USA. doi: 10.1073/pnas.95.13.7556 contributor: fullname: Kaplan – volume: 369 start-page: 31 year: 1994 ident: 2023072509252636000_R10 article-title: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice publication-title: Nature. doi: 10.1038/369031a0 contributor: fullname: Kagi – volume: 15 start-page: 749 year: 1997 ident: 2023072509252636000_R23 article-title: Cellular responses to interferon-γ publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.15.1.749 contributor: fullname: Boehm – volume: 286 start-page: 1957 year: 1999 ident: 2023072509252636000_R32 article-title: Perforin gene defects in familial hemophagocytic lymphohistiocytosis publication-title: Science. doi: 10.1126/science.286.5446.1957 contributor: fullname: Stepp – volume: 250 start-page: 1233 year: 1990 ident: 2023072509252636000_R15 article-title: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms publication-title: Science. doi: 10.1126/science.1978757 contributor: fullname: Malkin – volume: 73 start-page: 2527 year: 1999 ident: 2023072509252636000_R31 article-title: A role for perforin in downregulating T-cell responses during chronic viral infection publication-title: J. Virol. doi: 10.1128/JVI.73.3.2527-2536.1999 contributor: fullname: Matloubian – volume: 230 start-page: 221 year: 1998 ident: 2023072509252636000_R4 article-title: Natural killer cells and tumor therapy publication-title: Curr. Top. Microbiol. Immunol. contributor: fullname: Whiteside – volume: 184 start-page: 1781 year: 1996 ident: 2023072509252636000_R9 article-title: Decreased tumor surveillance in perforin-deficient mice publication-title: J. Exp. Med. doi: 10.1084/jem.184.5.1781 contributor: fullname: van den Broek – volume: 22 start-page: 3551 year: 1994 ident: 2023072509252636000_R13 article-title: Database of p53 gene somatic mutations in human tumors and cell lines publication-title: Nucleic Acids Res. contributor: fullname: Hollstein – volume: 47 start-page: 129 year: 1979 ident: 2023072509252636000_R25 article-title: Spontaneous tumors in nude miceeffect of the viable yellow gene publication-title: Exp. Cell Biol. contributor: fullname: Stutman – volume: 131 start-page: 2069 year: 1983 ident: 2023072509252636000_R26 article-title: Anti-mu induces lymphoma in germfree congenitally athymic (nude) but not in heterozygous (nu/+) mice publication-title: J. Immunol. doi: 10.4049/jimmunol.131.4.2069 contributor: fullname: Gershwin – volume: 187 start-page: 1903 year: 1998 ident: 2023072509252636000_R30 article-title: Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus publication-title: J. Exp. Med. doi: 10.1084/jem.187.11.1903 contributor: fullname: Binder – volume: 329 start-page: 1318 year: 1993 ident: 2023072509252636000_R14 article-title: Clinical implications of the p53 tumor-suppressor gene publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199310283291807 contributor: fullname: Harris – volume: 91 start-page: 10854 year: 1994 ident: 2023072509252636000_R18 article-title: Immune function in mice lacking the perforin gene publication-title: Proc. Natl. Acad. Sci. USA. doi: 10.1073/pnas.91.23.10854 contributor: fullname: Walsh – volume: 16 start-page: 194 year: 1995 ident: 2023072509252636000_R7 article-title: Perforinstructure and function publication-title: Immunol. Today. doi: 10.1016/0167-5699(95)80121-9 contributor: fullname: Liu |
| SSID | ssj0014456 |
| Score | 2.271005 |
| Snippet | Immune surveillance by cytotoxic lymphocytes against cancer has been postulated for decades, but direct evidence for the role of cytotoxic lymphocytes in... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 755 |
| SubjectTerms | Animals Brief Definitive Report CD8 antigen Cytotoxicity, Immunologic Graft Rejection Humans Lymphoma - etiology Lymphoma - immunology Membrane Glycoproteins - physiology Mice Mice, Inbred C57BL Neoplasm Transplantation Perforin Pore Forming Cytotoxic Proteins Tumor Suppressor Protein p53 - physiology |
| Title | Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/10974040 https://search.proquest.com/docview/17633777 https://search.proquest.com/docview/72243091 https://pubmed.ncbi.nlm.nih.gov/PMC2193269 |
| Volume | 192 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB4Bh6qXitIWQnnsoerNjr3e5xFFRTyaCilF4mZ512sRROwoOIj8-47XNgogLj17LK_nG3m-9Xw7A_Aj0jLKMK8GsbW4QTFSB0YWPBA8j6TNhWPGC2T_iLNrdnHDbzaA92dhvGjfmmlY3s_CcnrrtZXzmR32OrHh1XhEPevQw03YlEnSb9G70gFjfmSrl6k3EoCusWak2PDOzUJkNCEPJfcja3ClLGr-e6znpDdE87Veci0BnW7Dp445kpN2hZ9hw5U78GHc1ca_wOTKK9WnZTD24zdcTkaruqqrJzSoV-T8gfRzDQjakcly8eiamUMIO6kKMplXJTJFVy0fyO8VglzNsq9wffrr7-gs6EYmBJZTVgc5E9RkPJaRMZj7lRKqENpQmximnC6syCjVSlJkCrExRZxzXQjL8iQWGZM0-QZbZVW6PSCZ0dpIjsCppqNLojlz1GplrNOORfkAfvZOS-dtZ4zUV7QVS9HRKTo65Sk6egDHvUtTjN2mING-TBrjxy2RUr5vIZFhJEhpBrDbQrD2qBa7AcgX4DwbNH2zX17BcPL9s7vw2f_vO7_Dx_ZEvg4ifgBb9WLpDpGb1OYIWfn55ZGPyH-rjeV8 |
| link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o_lVR8Qt2QTx88jWlFtYbeqtC3qzYodRyywyarNIpZfz8RJ0LaIA5w9UWx948znzOcZgDeJlkmOcTVKncMDipU6srLkkeBFIl0hPLNBIHsspmfswzk_3wM-3IUJon1nl3H1bRVXy89BW7leufGgExufzCc0sA49vgE3cb9SORzS--QBY6FpaxCqtyKAvrRmotj4i1_FyGliHksemtbgXFnS_vnYjUp_UM3rismdEHR4Dz4Nk--UJ1_jTWNj9_NaXcd_Xt19uNuTUvKuG34Ae756CLfmfdr9ESxOggh-WUXz0NnDF2Sybeqm_oEGzZYcXZKhZQJBO7LYXHz3bTsj9ChSl2Sxriskob7eXJLZFv2nXuWP4ezw_elkGvXdGCLHKWuigglqc57KxFqkFUoJVQptqcssU16XTuSUaiUpkpDU2jItuC6FY0WWipxJmj2B_aqu_DMgudXaSo4-odpiMZnmzFOnlXVee5YUI3g7oGHWXdENE5LlihlE0CCChhtEcAQHA1YGt0Wb6-gWY1L8bmZSyr9bSCQvGbKlETztsN15VecUI5BXUP9t0JbkvjqCWIbS3D12z__7yQO4PT2dz8zs6PjjC7jTXfzXUcJfwn5zsfGvkAI19nVw-F_ytAaK |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkSouvB8LhfqAuOXl-HlEW1YtdKuVlkoVlyh2HHWBTVZtFrH99Z04CdoWcek5EyXWN44_Zz7PB_Ah1jLOcV0NEmtxg2KkDowseSB4EUtbCMeMF8ieiMNT9uWMn21ZfXnRvjWLsPq1DKvFuddWrpY2GnRi0Ww6pp516GhVlNF9eIBzlupho94XEBjzxq1erN4KAfr2mrFi0Q-3DJHXhDyU3BvX4PuyuP37sb0y_UM3b6smt5ahyWP4PgygU5_8DNeNCe3Vrd6OdxrhE3jUk1PyqQt5Cvdc9Qx2p335_TnMZ14Mv6iCqXf4cAUZb5q6qf9gQLMhR5dksE4gGEfm64vfrrU1wswidUnmq7pCMurq9SU53mAe1cv8BZxOPn8bHwa9K0NgOWVNUDBBTc4TGRuD9EIpoUqhDbWpYcrp0oqcUq0kRTKSGFMmBdelsKxIE5EzSdOXsFPVlXsNJDdaG8kxN1TbNCbVnDlqtTLWacfiYgQfB0SyVdd8I_NFc8UyRDFDFDOeIYoj2B_wynB6tDWPbjBZgt_PVEr5_wiJJCZF1jSCVx2-W4_qEmME8gbyfwPa1tw3ryCevkV3j9-bO9-5D7uzg0l2fHTy9S087M7_6yDme7DTXKzdO2RCjXnvc_4aK3oJCg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perforin-mediated+Cytotoxicity+Is+Critical+for+Surveillance+of+Spontaneous+Lymphoma&rft.jtitle=The+Journal+of+experimental+medicine&rft.au=Smyth%2C+MJ&rft.au=Thia%2C+KYT&rft.au=Street%2C+SEA&rft.au=MacGregor%2C+D&rft.date=2000-09-05&rft.issn=0022-1007&rft.eissn=1892-1007&rft.volume=192&rft.issue=5&rft.spage=755&rft.epage=760&rft_id=info:doi/10.1084%2Fjem.192.5.755&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1007&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1007&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1007&client=summon |